• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

    10/11/22 10:06:25 AM ET
    $ABC
    $ACMR
    $ADI
    $AMGN
    Other Pharmaceuticals
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $ABC alert in real time by email

    Upgrades

    According to Deutsche Bank, the prior rating for Scorpio Tankers Inc (NYSE:STNG) was changed from Sell to Hold. For the second quarter, Scorpio Tankers had an EPS of $3.13, compared to year-ago quarter EPS of $0.94. The stock has a 52-week-high of $46.30 and a 52-week-low of $11.02. At the end of the last trading period, Scorpio Tankers closed at $40.74.

    Credit Suisse upgraded the previous rating for Algonquin Power & Utilities Corp (NYSE:AQN) from Neutral to Outperform. For the second quarter, Algonquin Power had an EPS of $0.16, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $16.01 and a 52-week-low of $10.38. At the end of the last trading period, Algonquin Power closed at $10.48.

    For AmerisourceBergen Corp (NYSE:ABC), B of A Securities upgraded the previous rating of Neutral to Buy. AmerisourceBergen earned $2.62 in the third quarter, compared to $2.16 in the year-ago quarter. The current stock performance of AmerisourceBergen shows a 52-week-high of $167.19 and a 52-week-low of $127.94. Moreover, at the end of the last trading period, the closing price was at $137.62.

    According to Morgan Stanley, the prior rating for Amgen Inc (NASDAQ:AMGN) was changed from Equal-Weight to Overweight. For the second quarter, Amgen had an EPS of $4.65, compared to year-ago quarter EPS of $4.38. At the moment, the stock has a 52-week-high of $258.45 and a 52-week-low of $214.39. Amgen closed at $232.15 at the end of the last trading period.

    Benchmark upgraded the previous rating for Getty Images Holdings Inc (NYSE:GETY) from Hold to Buy. Getty Images Holdings earned $0.29 in the second quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Getty Images Holdings shows a 52-week-high of $37.88 and a 52-week-low of $5.75. Moreover, at the end of the last trading period, the closing price was at $6.27.

    For Seagen Inc (NASDAQ:SGEN), BMO Capital upgraded the previous rating of Market Perform to Outperform. In the second quarter, Seagen showed an EPS of $0.73, compared to $0.47 from the year-ago quarter. The current stock performance of Seagen shows a 52-week-high of $183.00 and a 52-week-low of $105.43. Moreover, at the end of the last trading period, the closing price was at $130.95.

    For Lululemon Athletica Inc (NASDAQ:LULU), Piper Sandler upgraded the previous rating of Neutral to Overweight. Lululemon Athletica earned $2.20 in the second quarter, compared to $1.65 in the year-ago quarter. The current stock performance of Lululemon Athletica shows a 52-week-high of $410.70 and a 52-week-low of $251.51. Moreover, at the end of the last trading period, the closing price was at $289.85.

    According to Piper Sandler, the prior rating for e.l.f. Beauty Inc (NYSE:ELF) was changed from Neutral to Overweight. For the first quarter, e.l.f. Beauty had an EPS of $0.39, compared to year-ago quarter EPS of $0.27. The stock has a 52-week-high of $41.31 and a 52-week-low of $20.49. At the end of the last trading period, e.l.f. Beauty closed at $37.49.

    Wells Fargo upgraded the previous rating for Marvell Technology Inc (NASDAQ:MRVL) from Equal-Weight to Overweight. For the second quarter, Marvell Tech had an EPS of $0.57, compared to year-ago quarter EPS of $0.34. The current stock performance of Marvell Tech shows a 52-week-high of $91.78 and a 52-week-low of $39.20. Moreover, at the end of the last trading period, the closing price was at $40.30.

    According to SVB Leerink, the prior rating for scPharmaceuticals Inc (NASDAQ:SCPH) was changed from Market Perform to Outperform. scPharmaceuticals earned $0.35 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.80 and a 52-week-low of $3.68. scPharmaceuticals closed at $4.02 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    According to UBS, the prior rating for BlackRock Inc (NYSE:BLK) was changed from Buy to Neutral. BlackRock earned $7.36 in the second quarter, compared to $10.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $927.48 and a 52-week-low of $541.33. BlackRock closed at $545.54 at the end of the last trading period.

    For ACM Research Inc (NASDAQ:ACMR), Jefferies downgraded the previous rating of Buy to Underperform. ACM Research earned $0.22 in the second quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $91.59 and a 52-week-low of $8.54. At the end of the last trading period, ACM Research closed at $9.04.

    According to Scotiabank, the prior rating for Mechel PAO (NYSE:MTL) was changed from Sector Outperform to Sector Perform. NoneThe stock has a 52-week-high of $4.32 and a 52-week-low of $1.88. At the end of the last trading period, Mechel PAO closed at $2.25.

    For Vitru Ltd (NASDAQ:VTRU), Goldman Sachs downgraded the previous rating of Buy to Neutral. Vitru earned $0.47 in the second quarter, compared to $0.18 in the year-ago quarter.

    Credit Suisse downgraded the previous rating for Cogent Communications Holdings Inc (NASDAQ:CCOI) from Outperform to Neutral. Cogent Comms Hldgs earned $0.24 in the second quarter, compared to $0.20 in the year-ago quarter. At the moment, the stock has a 52-week-high of $74.08 and a 52-week-low of $49.02. Cogent Comms Hldgs closed at $51.53 at the end of the last trading period.

    According to B of A Securities, the prior rating for SunPower Corp (NASDAQ:SPWR) was changed from Neutral to Underperform. SunPower earned $0.03 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $28.42 and a 52-week-low of $12.78. SunPower closed at $21.47 at the end of the last trading period.

    For Zoom Video Communications Inc (NASDAQ:ZM), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. Zoom Video Comms earned $1.05 in the second quarter, compared to $1.36 in the year-ago quarter. The current stock performance of Zoom Video Comms shows a 52-week-high of $184.91 and a 52-week-low of $71.69. Moreover, at the end of the last trading period, the closing price was at $73.72.

    For Meta Platforms Inc (NASDAQ:META), Atlantic Equities downgraded the previous rating of Overweight to Neutral. In the second quarter, Meta Platforms showed an EPS of $2.46, compared to $3.61 from the year-ago quarter. The current stock performance of Meta Platforms shows a 52-week-high of $199.45 and a 52-week-low of $11.73. Moreover, at the end of the last trading period, the closing price was at $133.79.

    According to Wells Fargo, the prior rating for Skyworks Solutions Inc (NASDAQ:SWKS) was changed from Overweight to Equal-Weight. In the third quarter, Skyworks Solutions showed an EPS of $2.44, compared to $2.15 from the year-ago quarter. The current stock performance of Skyworks Solutions shows a 52-week-high of $163.47 and a 52-week-low of $83.28. Moreover, at the end of the last trading period, the closing price was at $83.92.

    Wells Fargo downgraded the previous rating for Qorvo Inc (NASDAQ:QRVO) from Overweight to Equal-Weight. For the first quarter, Qorvo had an EPS of $2.25, compared to year-ago quarter EPS of $2.83. The current stock performance of Qorvo shows a 52-week-high of $163.12 and a 52-week-low of $79.36. Moreover, at the end of the last trading period, the closing price was at $81.96.

    See all analyst ratings downgrades.

    Initiations

    With a Equal-Weight rating, Morgan Stanley initiated coverage on Nurix Therapeutics Inc (NASDAQ:NRIX). The price target seems to have been set at $11.00 for Nurix Therapeutics. For the third quarter, Nurix Therapeutics had an EPS of $0.90, compared to year-ago quarter EPS of $0.65. The current stock performance of Nurix Therapeutics shows a 52-week-high of $30.52 and a 52-week-low of $7.52. Moreover, at the end of the last trading period, the closing price was at $10.99.

    JP Morgan initiated coverage on CompoSecure Inc (NASDAQ:CMPO) with an Overweight rating. The price target for CompoSecure is set to $10.00. The stock has a 52-week-high of $9.09 and a 52-week-low of $4.72. At the end of the last trading period, CompoSecure closed at $5.26.

    With a Buy rating, Canaccord Genuity initiated coverage on Rapid7 Inc (NASDAQ:RPD). The price target seems to have been set at $60.00 for Rapid7. For the second quarter, Rapid7 had an EPS of $0.01, compared to year-ago quarter EPS of $0.07. The stock has a 52-week-high of $118.42 and a 52-week-low of $39.67. At the end of the last trading period, Rapid7 closed at $39.89.

    With a Buy rating, Canaccord Genuity initiated coverage on Qualys Inc (NASDAQ:QLYS). The price target seems to have been set at $180.00 for Qualys. For the second quarter, Qualys had an EPS of $0.89, compared to year-ago quarter EPS of $0.79. At the moment, the stock has a 52-week-high of $162.36 and a 52-week-low of $108.10. Qualys closed at $131.12 at the end of the last trading period.

    With a Buy rating, Maxim Group initiated coverage on Xperi Inc (NYSE:XPER). The price target seems to have been set at $23.00 for Xperi. Xperi earned $0.52 in the second quarter, compared to $0.61 in the year-ago quarter. The stock has a 52-week-high of $19.90 and a 52-week-low of $13.30. At the end of the last trading period, Xperi closed at $13.74.

    Wedbush initiated coverage on Brown-Forman Corp (NYSE:BF) with a Neutral rating. The price target for Brown-Forman is set to $70.00.

    With a Neutral rating, Mizuho initiated coverage on Eastman Chemical Co (NYSE:EMN). The price target seems to have been set at $91.00 for Eastman Chemical. In the second quarter, Eastman Chemical showed an EPS of $2.83, compared to $2.46 from the year-ago quarter. The current stock performance of Eastman Chemical shows a 52-week-high of $129.47 and a 52-week-low of $69.91. Moreover, at the end of the last trading period, the closing price was at $71.78.

    With a Buy rating, Goldman Sachs initiated coverage on Enovis Corp (NYSE:ENOV). The price target seems to have been set at $57.00 for Enovis. For the second quarter, Enovis had an EPS of $0.59, compared to year-ago quarter EPS of $1.68. The stock has a 52-week-high of $72.13 and a 52-week-low of $44.77. At the end of the last trading period, Enovis closed at $44.86.

    With a Market Perform rating, Cowen & Co. initiated coverage on Texas Instruments Inc (NASDAQ:TXN). The price target seems to have been set at $170.00 for Texas Instruments. Texas Instruments earned $2.45 in the second quarter, compared to $2.05 in the year-ago quarter. The stock has a 52-week-high of $192.10 and a 52-week-low of $144.46. At the end of the last trading period, Texas Instruments closed at $156.79.

    Cowen & Co. initiated coverage on Analog Devices Inc (NASDAQ:ADI) with an Outperform rating. The price target for Analog Devices is set to $180.00. For the third quarter, Analog Devices had an EPS of $2.52, compared to year-ago quarter EPS of $1.72. At the moment, the stock has a 52-week-high of $180.01 and a 52-week-low of $138.50. Analog Devices closed at $140.90 at the end of the last trading period.

    With an Overweight rating, Morgan Stanley initiated coverage on Intellia Therapeutics Inc (NASDAQ:NTLA). The price target seems to have been set at $84.00 for Intellia Therapeutics. Intellia Therapeutics earned $1.33 in the second quarter, compared to $1.01 in the year-ago quarter. The current stock performance of Intellia Therapeutics shows a 52-week-high of $119.65 and a 52-week-low of $37.08. Moreover, at the end of the last trading period, the closing price was at $54.31.

    Morgan Stanley initiated coverage on United Therapeutics Corp (NASDAQ:UTHR) with an Overweight rating. The price target for United Therapeutics is set to $288.00. In the second quarter, United Therapeutics showed an EPS of $2.41, compared to $3.65 from the year-ago quarter. The stock has a 52-week-high of $245.48 and a 52-week-low of $158.38. At the end of the last trading period, United Therapeutics closed at $205.95.

    Morgan Stanley initiated coverage on Arcus Biosciences Inc (NYSE:RCUS) with an Overweight rating. The price target for Arcus Biosciences is set to $40.00. Arcus Biosciences earned $0.93 in the second quarter, compared to $1.09 in the year-ago quarter. The stock has a 52-week-high of $42.05 and a 52-week-low of $16.74. At the end of the last trading period, Arcus Biosciences closed at $26.15.

    With an Underweight rating, Morgan Stanley initiated coverage on CRISPR Therapeutics AG (NASDAQ:CRSP). The price target seems to have been set at $37.00 for CRISPR Therapeutics. For the second quarter, CRISPR Therapeutics had an EPS of $2.40, compared to year-ago quarter EPS of $9.44. The stock has a 52-week-high of $86.95 and a 52-week-low of $42.51. At the end of the last trading period, CRISPR Therapeutics closed at $60.82.

    Morgan Stanley initiated coverage on C4 Therapeutics Inc (NASDAQ:CCCC) with an Underweight rating. The price target for C4 Therapeutics is set to $6.00. For the second quarter, C4 Therapeutics had an EPS of $0.56, compared to year-ago quarter EPS of $0.51. The stock has a 52-week-high of $33.76 and a 52-week-low of $4.84. At the end of the last trading period, C4 Therapeutics closed at $7.73.

    Morgan Stanley initiated coverage on Revance Therapeutics Inc (NASDAQ:RVNC) with a Equal-Weight rating. The price target for Revance Therapeutics is set to $27.00. Revance Therapeutics earned $0.88 in the second quarter, compared to $1.07 in the year-ago quarter. The stock has a 52-week-high of $30.95 and a 52-week-low of $11.27. At the end of the last trading period, Revance Therapeutics closed at $28.89.

    UBS initiated coverage on Rani Therapeutics Holdings Inc (NASDAQ:RANI) with a Buy rating. The price target for Rani Therapeutics Hldgs is set to $15.00. For the second quarter, Rani Therapeutics Hldgs had an EPS of $0.31, compared to year-ago quarter EPS of $0.12. The current stock performance of Rani Therapeutics Hldgs shows a 52-week-high of $27.13 and a 52-week-low of $6.73. Moreover, at the end of the last trading period, the closing price was at $7.00.

    UBS initiated coverage on Neurocrine Biosciences Inc (NASDAQ:NBIX) with a Buy rating. The price target for Neurocrine Biosciences is set to $136.00. In the second quarter, Neurocrine Biosciences showed an EPS of $0.84, compared to $0.63 from the year-ago quarter. The current stock performance of Neurocrine Biosciences shows a 52-week-high of $113.63 and a 52-week-low of $71.88. Moreover, at the end of the last trading period, the closing price was at $106.84.

    UBS initiated coverage on Cytokinetics Inc (NASDAQ:CYTK) with a Buy rating. The price target for Cytokinetics is set to $80.00. For the second quarter, Cytokinetics had an EPS of $0.23, compared to year-ago quarter EPS of $0.86. The current stock performance of Cytokinetics shows a 52-week-high of $55.80 and a 52-week-low of $29.26. Moreover, at the end of the last trading period, the closing price was at $47.23.

    With an Underweight rating, Barclays initiated coverage on Roblox Corp (NYSE:RBLX). The price target seems to have been set at $20.00 for Roblox. In the second quarter, Roblox showed an EPS of $0.30, compared to $0.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $103.79 and a 52-week-low of $21.65. Roblox closed at $35.40 at the end of the last trading period.

    With a Neutral rating, Citigroup initiated coverage on Corebridge Financial Inc (NYSE:CRBG). The price target seems to have been set at $23.00 for Corebridge Financial. The stock has a 52-week-high of $22.00 and a 52-week-low of $19.14. At the end of the last trading period, Corebridge Financial closed at $19.69.

    Wells Fargo initiated coverage on Elastic NV (NYSE:ESTC) with an Underweight rating. The price target for Elastic is set to $73.00. Elastic earned $0.15 in the first quarter, compared to $0.04 in the year-ago quarter. The current stock performance of Elastic shows a 52-week-high of $124.25 and a 52-week-low of $50.74. Moreover, at the end of the last trading period, the closing price was at $66.78.

    Bernstein initiated coverage on Snowflake Inc (NYSE:SNOW) with a Market Perform rating. Snowflake earned $0.01 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $344.00 and a 52-week-low of $110.27. Snowflake closed at $159.05 at the end of the last trading period.

    Wells Fargo initiated coverage on Splunk Inc (NASDAQ:SPLK) with an Overweight rating. The price target for Splunk is set to $95.00. Splunk earned $0.09 in the second quarter, compared to $0.62 in the year-ago quarter. The current stock performance of Splunk shows a 52-week-high of $150.79 and a 52-week-low of $71.11. Moreover, at the end of the last trading period, the closing price was at $72.12.

    With an Overweight rating, Wells Fargo initiated coverage on Datadog Inc (NASDAQ:DDOG). The price target seems to have been set at $120.00 for Datadog. Datadog earned $0.24 in the second quarter, compared to $0.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of $184.70 and a 52-week-low of $81.12. Datadog closed at $84.02 at the end of the last trading period.

    With an Overweight rating, Wells Fargo initiated coverage on Dynatrace Inc (NYSE:DT). The price target seems to have been set at $45.00 for Dynatrace. Dynatrace earned $0.18 in the first quarter, compared to $0.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.17 and a 52-week-low of $29.41. Dynatrace closed at $34.69 at the end of the last trading period.

    With a Buy rating, Deutsche Bank initiated coverage on International Seaways Inc (NYSE:INSW). The price target seems to have been set at $40.00 for International Seaways. International Seaways earned $1.43 in the second quarter, compared to $0.51 in the year-ago quarter. The current stock performance of International Seaways shows a 52-week-high of $36.72 and a 52-week-low of $13.05. Moreover, at the end of the last trading period, the closing price was at $34.31.

    With a Buy rating, Goldman Sachs initiated coverage on Warner Music Group Corp (NASDAQ:WMG). The price target seems to have been set at $32.00 for Warner Music Group. For the third quarter, Warner Music Group had an EPS of $0.28, compared to year-ago quarter EPS of $0.16. At the moment, the stock has a 52-week-high of $44.64 and a 52-week-low of $22.08. Warner Music Group closed at $22.35 at the end of the last trading period.

    Mizuho initiated coverage on Celanese Corp (NYSE:CE) with a Neutral rating. The price target for Celanese is set to $116.00. Celanese earned $4.99 in the second quarter, compared to $5.02 in the year-ago quarter. The current stock performance of Celanese shows a 52-week-high of $176.50 and a 52-week-low of $86.70. Moreover, at the end of the last trading period, the closing price was at $91.85.

    Oppenheimer initiated coverage on POINT Biopharma Global Inc (NASDAQ:PNT) with an Outperform rating. The price target for POINT Biopharma Global is set to $20.00. For the second quarter, POINT Biopharma Global had an EPS of $0.27, compared to year-ago quarter EPS of $0.15. The current stock performance of POINT Biopharma Global shows a 52-week-high of $10.98 and a 52-week-low of $5.22. Moreover, at the end of the last trading period, the closing price was at $7.28.

    With an Outperform rating, Wedbush initiated coverage on Keurig Dr Pepper Inc (NASDAQ:KDP). The price target seems to have been set at $43.00 for Keurig Dr Pepper. In the second quarter, Keurig Dr Pepper showed an EPS of $0.39, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $41.31 and a 52-week-low of $33.35. At the end of the last trading period, Keurig Dr Pepper closed at $36.97.

    With a Neutral rating, Wedbush initiated coverage on Monster Beverage Corp (NASDAQ:MNST). The price target seems to have been set at $95.00 for Monster Beverage. Monster Beverage earned $0.51 in the second quarter, compared to $0.75 in the year-ago quarter. The stock has a 52-week-high of $99.81 and a 52-week-low of $71.78. At the end of the last trading period, Monster Beverage closed at $91.02.

    With an Outperform rating, Wedbush initiated coverage on Coca-Cola Co (NYSE:KO). The price target seems to have been set at $63.00 for Coca-Cola. Coca-Cola earned $0.70 in the second quarter, compared to $0.68 in the year-ago quarter. At the moment, the stock has a 52-week-high of $67.20 and a 52-week-low of $54.02. Coca-Cola closed at $54.39 at the end of the last trading period.

    With a Neutral rating, Wedbush initiated coverage on Boston Beer Co Inc (NYSE:SAM). The price target seems to have been set at $350.00 for Boston Beer Co. Boston Beer Co earned $4.31 in the second quarter, compared to $4.75 in the year-ago quarter. The current stock performance of Boston Beer Co shows a 52-week-high of $535.00 and a 52-week-low of $287.00. Moreover, at the end of the last trading period, the closing price was at $348.25.

    Wedbush initiated coverage on The Duckhorn Portfolio Inc (NYSE:NAPA) with an Outperform rating. The price target for Duckhorn Portfolio is set to $18.00. Duckhorn Portfolio earned $0.08 in the fourth quarter, compared to $0.08 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.57 and a 52-week-low of $12.64. Duckhorn Portfolio closed at $14.43 at the end of the last trading period.

    With an Outperform rating, Wedbush initiated coverage on PepsiCo Inc (NASDAQ:PEP). The price target seems to have been set at $185.00 for PepsiCo. PepsiCo earned $1.86 in the second quarter, compared to $1.72 in the year-ago quarter. The stock has a 52-week-high of $181.07 and a 52-week-low of $153.37. At the end of the last trading period, PepsiCo closed at $161.82.

    With an Outperform rating, Wedbush initiated coverage on MGP Ingredients Inc (NASDAQ:MGPI). The price target seems to have been set at $125.00 for MGP Ingredients. For the second quarter, MGP Ingredients had an EPS of $1.15, compared to year-ago quarter EPS of $1.27. The stock has a 52-week-high of $117.01 and a 52-week-low of $73.02. At the end of the last trading period, MGP Ingredients closed at $105.04.

    Wedbush initiated coverage on Constellation Brands Inc (NYSE:STZ) with an Outperform rating. The price target for Constellation Brands is set to $275.00. Constellation Brands earned $3.17 in the second quarter, compared to $2.38 in the year-ago quarter. The current stock performance of Constellation Brands shows a 52-week-high of $261.52 and a 52-week-low of $207.59. Moreover, at the end of the last trading period, the closing price was at $221.24.

    With a Neutral rating, Wedbush initiated coverage on Molson Coors Beverage Co (NYSE:TAP). The price target seems to have been set at $50.00 for Molson Coors Beverage. In the second quarter, Molson Coors Beverage showed an EPS of $1.19, compared to $1.58 from the year-ago quarter. The stock has a 52-week-high of $60.12 and a 52-week-low of $46.47. At the end of the last trading period, Molson Coors Beverage closed at $47.31.

    Wedbush initiated coverage on Celsius Holdings Inc (NASDAQ:CELH) with a Neutral rating. The price target for Celsius Holdings is set to $90.00. In the second quarter, Celsius Holdings showed an EPS of $0.12, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $118.19 and a 52-week-low of $38.31. Celsius Holdings closed at $89.24 at the end of the last trading period.

    Wolfe Research initiated coverage on Virgin Galactic Holdings Inc (NYSE:SPCE) with an Underperform rating. The price target for Virgin Galactic Hldgs is set to $4.00. In the second quarter, Virgin Galactic Hldgs showed an EPS of $0.43, compared to $0.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of $13.73 and a 52-week-low of $4.68. Virgin Galactic Hldgs closed at $4.92 at the end of the last trading period.

    With an Underperform rating, Wolfe Research initiated coverage on Spirit AeroSystems Holdings Inc (NYSE:SPR). The price target seems to have been set at $24.00 for Spirit AeroSystems Hldgs. Spirit AeroSystems Hldgs earned $1.21 in the second quarter, compared to $0.31 in the year-ago quarter. The current stock performance of Spirit AeroSystems Hldgs shows a 52-week-high of $53.31 and a 52-week-low of $21.51. Moreover, at the end of the last trading period, the closing price was at $24.95.

    With an Underperform rating, Wolfe Research initiated coverage on Triumph Group Inc (NYSE:TGI). The price target seems to have been set at $9.00 for Triumph Group. In the first quarter, Triumph Group showed an EPS of $0.12, compared to $0.09 from the year-ago quarter. At the moment, the stock has a 52-week-high of $27.85 and a 52-week-low of $8.58. Triumph Group closed at $8.93 at the end of the last trading period.

    Wolfe Research initiated coverage on Woodward Inc (NASDAQ:WWD) with an Outperform rating. The price target for Woodward is set to $100.00. Woodward earned $0.64 in the third quarter, compared to $0.74 in the year-ago quarter. The stock has a 52-week-high of $129.12 and a 52-week-low of $79.26. At the end of the last trading period, Woodward closed at $84.43.

    For Barnes Group Inc (NYSE:B), Wolfe Research initiated coverage, by setting the current rating at Peer Perform. For the second quarter, Barnes Gr had an EPS of $0.56, compared to year-ago quarter EPS of $0.45. The stock has a 52-week-high of $48.79 and a 52-week-low of $27.93. At the end of the last trading period, Barnes Gr closed at $32.06.

    Wolfe Research initiated coverage on TransDigm Group Inc (NYSE:TDG) with an Outperform rating. The price target for TransDigm Gr is set to $650.00. TransDigm Gr earned $4.85 in the third quarter, compared to $3.33 in the year-ago quarter. The stock has a 52-week-high of $684.72 and a 52-week-low of $500.08. At the end of the last trading period, TransDigm Gr closed at $531.52.

    Wolfe Research initiated coverage on Raytheon Technologies Corp (NYSE:RTX) with a Peer Perform rating. Raytheon Technologies earned $1.16 in the second quarter, compared to $1.03 in the year-ago quarter. The current stock performance of Raytheon Technologies shows a 52-week-high of $106.02 and a 52-week-low of $80.27. Moreover, at the end of the last trading period, the closing price was at $84.16.

    With an Outperform rating, Wolfe Research initiated coverage on Northrop Grumman Corp (NYSE:NOC). The price target seems to have been set at $565.00 for Northrop Grumman. Northrop Grumman earned $6.06 in the second quarter, compared to $6.42 in the year-ago quarter. The current stock performance of Northrop Grumman shows a 52-week-high of $515.49 and a 52-week-low of $364.62. Moreover, at the end of the last trading period, the closing price was at $503.83.

    Wolfe Research initiated coverage on Curtiss-Wright Corp (NYSE:CW) with an Outperform rating. The price target for Curtiss-Wright is set to $170.00. Curtiss-Wright earned $1.83 in the second quarter, compared to $1.56 in the year-ago quarter. The current stock performance of Curtiss-Wright shows a 52-week-high of $162.98 and a 52-week-low of $124.37. Moreover, at the end of the last trading period, the closing price was at $148.43.

    Wolfe Research initiated coverage on Lockheed Martin Corp (NYSE:LMT) with a Peer Perform rating. Lockheed Martin earned $6.32 in the second quarter, compared to $6.52 in the year-ago quarter. At the moment, the stock has a 52-week-high of $479.99 and a 52-week-low of $353.03. Lockheed Martin closed at $409.99 at the end of the last trading period.

    Wolfe Research initiated coverage on Embraer SA (NYSE:ERJ) with an Outperform rating. The price target for Embraer is set to $14.00. In the second quarter, Embraer showed an EPS of $0.21, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $18.08 and a 52-week-low of $7.91. Embraer closed at $9.55 at the end of the last trading period.

    Wolfe Research initiated coverage on L3Harris Technologies Inc (NYSE:LHX) with a Peer Perform rating. In the second quarter, L3Harris Technologies showed an EPS of $3.23, compared to $3.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $279.71 and a 52-week-low of $206.04. L3Harris Technologies closed at $230.44 at the end of the last trading period.

    With an Outperform rating, Wolfe Research initiated coverage on General Dynamics Corp (NYSE:GD). The price target seems to have been set at $265.00 for General Dynamics. General Dynamics earned $2.75 in the second quarter, compared to $2.61 in the year-ago quarter. The current stock performance of General Dynamics shows a 52-week-high of $254.99 and a 52-week-low of $200.65. Moreover, at the end of the last trading period, the closing price was at $225.41.

    For Hexcel Corp (NYSE:HXL), Wolfe Research initiated coverage, by setting the current rating at Peer Perform. In the second quarter, Hexcel showed an EPS of $0.33, compared to $0.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $65.82 and a 52-week-low of $47.38. Hexcel closed at $54.06 at the end of the last trading period.

    Wolfe Research initiated coverage on Heico Corp (NYSE:HEI) with a Peer Perform rating. In the third quarter, Heico showed an EPS of $0.60, compared to $0.56 from the year-ago quarter. The current stock performance of Heico shows a 52-week-high of $165.61 and a 52-week-low of $126.95. Moreover, at the end of the last trading period, the closing price was at $148.92.

    Wolfe Research initiated coverage on Huntington Ingalls Industries Inc (NYSE:HII) with an Outperform rating. The price target for Huntington Ingalls Indus is set to $315.00. For the second quarter, Huntington Ingalls Indus had an EPS of $4.44, compared to year-ago quarter EPS of $3.20. The stock has a 52-week-high of $243.46 and a 52-week-low of $177.20. At the end of the last trading period, Huntington Ingalls Indus closed at $235.06.

    Wolfe Research initiated coverage on Boeing Co (NYSE:BA) with an Outperform rating. The price target for Boeing is set to $180.00. In the second quarter, Boeing showed an EPS of $0.37, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $229.67 and a 52-week-low of $113.02. Boeing closed at $131.90 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $ABC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABC
    $ACMR
    $ADI
    $AMGN

    CompanyDatePrice TargetRatingAnalyst
    Rapid7 Inc.
    $RPD
    2/11/2026$9.00Buy → Neutral
    UBS
    Rapid7 Inc.
    $RPD
    2/11/2026$10.00Buy → Hold
    Canaccord Genuity
    Roblox Corporation
    $RBLX
    2/9/2026$84.00Neutral → Buy
    Roth Capital
    Roblox Corporation
    $RBLX
    2/6/2026$159.00 → $105.00Buy
    Needham
    Transdigm Group Incorporated
    $TDG
    2/5/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Celanese Corporation
    $CE
    2/5/2026$86.00Hold → Buy
    Jefferies
    Transdigm Group Incorporated
    $TDG
    2/4/2026$1400.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ABC
    $ACMR
    $ADI
    $AMGN
    SEC Filings

    View All

    SEC Form 144 filed by BlackRock Inc.

    144 - BlackRock, Inc. (0002012383) (Subject)

    2/11/26 6:48:15 PM ET
    $BLK
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 144 filed by BlackRock Inc.

    144 - BlackRock, Inc. (0002012383) (Subject)

    2/11/26 6:27:31 PM ET
    $BLK
    Investment Bankers/Brokers/Service
    Finance

    Skyworks Solutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - SKYWORKS SOLUTIONS, INC. (0000004127) (Filer)

    2/11/26 5:18:20 PM ET
    $SWKS
    Semiconductors
    Technology

    $ABC
    $ACMR
    $ADI
    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MGP Ingredients to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 25, 2026

    MGP Ingredients, Inc. (NASDAQ:MGPI), a leading provider of branded and distilled spirits and food ingredient solutions, today announced that it will report results for the fourth quarter and full year ended December 31, 2025, on Wednesday, February 25, at 10 a.m. ET. The company expects to release its financial results before the markets open. Management, including Julie Francis, President and CEO, Brandon Gall, CFO, will hold a conference call to discuss these results. Please visit the "News and Events" section of the company's Investor Relations section at ir.mgpingredients.com/news-events to access the live webcast. Investors can also dial 844-308-6398 (domestic) or 412-717-9605 (int

    2/11/26 5:30:00 PM ET
    $MGPI
    Beverages (Production/Distribution)
    Consumer Staples

    International Seaways to Announce Fourth Quarter and Full Year 2025 Results on February 26, 2026

    International Seaways, Inc. (NYSE:INSW) (the "Company" or "INSW") announced today that it plans to release fourth quarter and full year 2025 results before market open on Thursday, February 26, 2026. The Company will host a conference call for investors at 9:00 a.m. Eastern Time ("ET") on the same day. Conference Call Details: Date: Thursday, February 26, 2026 Time 9:00 AM ET Dial-in Numbers US: +1 (833) 470-1428   International: +1 (929) 526-1599 Conference ID 699376 A live webcast of the conference call will be available from the Investor Relations section of the Company's website at https://www.intlseas.com/.

    2/11/26 5:00:00 PM ET
    $INSW
    Marine Transportation
    Consumer Discretionary

    Curtiss-Wright Reports Fourth Quarter and Full-Year 2025 Financial Results; Full-Year 2026 Outlook Reflects Higher Sales, Operating Margin Expansion, Double-Digit EPS Growth and Strong Free Cash Flow

    Company Delivers Record FY25 Sales, Profitability, EPS, Free Cash Flow and Orders Curtiss-Wright Corporation (NYSE:CW) reports financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights: Reported sales of $947 million, up 15%, operating income of $182 million, operating margin of 19.2%, and diluted earnings per share (EPS) of $3.69; Adjusted operating income of $187 million, up 14%; Adjusted operating margin of 19.7%; Adjusted diluted EPS of $3.79, up 16%; Free cash flow (FCF) of $315 million, generating 224% FCF conversion; Total share repurchases of $140 million; and New orders of $1.1 billion, up 18%, generating

    2/11/26 4:30:00 PM ET
    $CW
    Industrial Machinery/Components
    Technology

    $ABC
    $ACMR
    $ADI
    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Lisman Michael bought $1,220,048 worth of shares (950 units at $1,284.26), increasing direct ownership by 41% to 3,259 units (SEC Form 4)

    4 - TransDigm Group INC (0001260221) (Issuer)

    2/9/26 4:30:19 PM ET
    $TDG
    Military/Government/Technical
    Industrials

    Director Cocks Christian P bought $2,123 worth of Class B Common Stock (45 units at $47.19), increasing direct ownership by 0.98% to 4,634 units (SEC Form 4)

    4 - MOLSON COORS BEVERAGE CO (0000024545) (Issuer)

    2/6/26 7:20:21 PM ET
    $TAP
    Beverages (Production/Distribution)
    Consumer Staples

    Chief Medical Officer Patel Naimish bought $49,704 worth of shares (1,508 units at $32.96) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    1/27/26 5:35:15 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABC
    $ACMR
    $ADI
    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Off. & Corp. Sec. Reinstra Mark converted options into 118,110 shares and sold $2,493,475 worth of shares (34,320 units at $72.65), increasing direct ownership by 23% to 454,322 units (SEC Form 4)

    4 - Roblox Corp (0001315098) (Issuer)

    2/11/26 6:57:26 PM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    Chief People & Systems Officer Chakravarthy Arvind converted options into 114,776 units of Class A Common Stock and sold $6,639,886 worth of Class A Common Stock (95,895 units at $69.24), increasing direct ownership by 33% to 240,570 units (SEC Form 4)

    4 - Roblox Corp (0001315098) (Issuer)

    2/11/26 6:56:36 PM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    President & CEO Baszucki David converted options into 893,068 shares and sold $19,782,756 worth of shares (272,269 units at $72.66), increasing direct ownership by 326% to 811,373 units (SEC Form 4)

    4 - Roblox Corp (0001315098) (Issuer)

    2/11/26 6:55:53 PM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    $ABC
    $ACMR
    $ADI
    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rapid7 downgraded by UBS with a new price target

    UBS downgraded Rapid7 from Buy to Neutral and set a new price target of $9.00

    2/11/26 8:18:36 AM ET
    $RPD
    Computer Software: Prepackaged Software
    Technology

    Rapid7 downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Rapid7 from Buy to Hold and set a new price target of $10.00

    2/11/26 7:50:43 AM ET
    $RPD
    Computer Software: Prepackaged Software
    Technology

    Roblox upgraded by Roth Capital with a new price target

    Roth Capital upgraded Roblox from Neutral to Buy and set a new price target of $84.00

    2/9/26 6:58:32 AM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    $ABC
    $ACMR
    $ADI
    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABC
    $ACMR
    $ADI
    $AMGN
    Financials

    Live finance-specific insights

    View All

    MGP Ingredients to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 25, 2026

    MGP Ingredients, Inc. (NASDAQ:MGPI), a leading provider of branded and distilled spirits and food ingredient solutions, today announced that it will report results for the fourth quarter and full year ended December 31, 2025, on Wednesday, February 25, at 10 a.m. ET. The company expects to release its financial results before the markets open. Management, including Julie Francis, President and CEO, Brandon Gall, CFO, will hold a conference call to discuss these results. Please visit the "News and Events" section of the company's Investor Relations section at ir.mgpingredients.com/news-events to access the live webcast. Investors can also dial 844-308-6398 (domestic) or 412-717-9605 (int

    2/11/26 5:30:00 PM ET
    $MGPI
    Beverages (Production/Distribution)
    Consumer Staples

    International Seaways to Announce Fourth Quarter and Full Year 2025 Results on February 26, 2026

    International Seaways, Inc. (NYSE:INSW) (the "Company" or "INSW") announced today that it plans to release fourth quarter and full year 2025 results before market open on Thursday, February 26, 2026. The Company will host a conference call for investors at 9:00 a.m. Eastern Time ("ET") on the same day. Conference Call Details: Date: Thursday, February 26, 2026 Time 9:00 AM ET Dial-in Numbers US: +1 (833) 470-1428   International: +1 (929) 526-1599 Conference ID 699376 A live webcast of the conference call will be available from the Investor Relations section of the Company's website at https://www.intlseas.com/.

    2/11/26 5:00:00 PM ET
    $INSW
    Marine Transportation
    Consumer Discretionary

    Curtiss-Wright Reports Fourth Quarter and Full-Year 2025 Financial Results; Full-Year 2026 Outlook Reflects Higher Sales, Operating Margin Expansion, Double-Digit EPS Growth and Strong Free Cash Flow

    Company Delivers Record FY25 Sales, Profitability, EPS, Free Cash Flow and Orders Curtiss-Wright Corporation (NYSE:CW) reports financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights: Reported sales of $947 million, up 15%, operating income of $182 million, operating margin of 19.2%, and diluted earnings per share (EPS) of $3.69; Adjusted operating income of $187 million, up 14%; Adjusted operating margin of 19.7%; Adjusted diluted EPS of $3.79, up 16%; Free cash flow (FCF) of $315 million, generating 224% FCF conversion; Total share repurchases of $140 million; and New orders of $1.1 billion, up 18%, generating

    2/11/26 4:30:00 PM ET
    $CW
    Industrial Machinery/Components
    Technology

    $ABC
    $ACMR
    $ADI
    $AMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Celsius Holdings Appoints Christy Jacoby and John Short to the Company's Board of Directors

    Celsius Holdings, Inc. (NASDAQ:CELH) ("Celsius Holdings" or "the Company") today announced the appointment of Christy Jacoby and John Short to its Board of Directors. Jacoby and Short were nominated by PepsiCo, Inc. ("PepsiCo") following the resignation of Israel Kontorovsky and Michael Del Pozzo from the Celsius Holdings Board, effective immediately. "We thank Israel and Mike for their service and contributions during an important period of growth and evolution for Celsius Holdings," said John Fieldly, Chairman and Chief Executive Officer of Celsius Holdings. "As we continue to scale with discipline, operating rigor and portfolio clarity, we believe Christy and John bring highly relevant

    2/10/26 4:30:00 PM ET
    $CELH
    Beverages (Production/Distribution)
    Consumer Staples

    TTM Technologies, Inc. Appoints Two New Independent Directors

    SANTA ANA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- TTM Technologies, Inc. (NASDAQ:TTMI), a leading global manufacturer of technology products, including mission systems, radio frequency ("RF") components and RF microwave/microelectronic assemblies, and technologically advanced interconnect solutions, including printed circuit boards ("PCB") and substrates, today announced that, after long and distinguished careers with TTM, Thomas Edman, the Company's former President and Chief Executive Officer and a current Class I member of the Board of Directors (the "Board"), and John Mayer, a current Class III member of the Board, will retire from the Board effective as of May 7, 2026, immediately

    2/2/26 7:00:00 AM ET
    $CACI
    $DCO
    $TTMI
    EDP Services
    Technology
    Military/Government/Technical
    Industrials

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABC
    $ACMR
    $ADI
    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BlackRock Inc.

    SC 13G/A - BlackRock, Inc. (0002012383) (Filed by)

    12/6/24 4:32:58 PM ET
    $BLK
    Investment Bankers/Brokers/Service
    Finance